Bortezomib was further reported to prevent bone metastasis of prostate cancer cells by inhibition of the WW domain containing E3 ubiquitin protein ligase 1 (WWP1) and Smurf ligases, which are frequently upregulated in patients with bone metastasis [254]. This evidence concerns the gene WWP1 and prostate carcinoma.